Clinical Deterioration Rate in Intermediate-Risk Pulmonary Embolism
Approximately 9-10 patients out of 100 with hemodynamically stable intermediate-risk pulmonary embolism will experience clinical deterioration, though this varies significantly based on specific risk factors present at admission.
Evidence-Based Deterioration Rates
The most recent guideline data from the 2026 AHA/ACC/ACCP guidelines indicates that 8.8% of intermediate-high risk PE patients experienced clinical deterioration within 48 hours in the Italian Pulmonary Embolism Registry 1. This aligns closely with research showing deterioration rates of 10.5% in a large prospective study of 370 intermediate-risk patients 2.
However, the overall intermediate-risk category encompasses a wide spectrum:
- Intermediate-high risk patients: 9-15% deterioration rate 3, 4
- Intermediate-low risk patients: Substantially lower rates (not well-defined in provided evidence)
- Selected high-risk subgroups: Up to 24% complicated course 4
Critical Time Window
The first 24-72 hours represent the highest risk period for deterioration 1. In the PEITHO trial, hemodynamic collapse occurred at a mean of 1.5-1.79 days after diagnosis 1. This narrow window demands intensive monitoring during the initial hospitalization phase.
Key Risk Stratifiers That Modify This Baseline Risk
Mean Arterial Pressure (MAP)
- MAP >80 mmHg: Only 2.3% risk of deterioration (negative predictive value 97.7%) 1, 3
- MAP ≤81.5 mmHg: 3.25-fold increased risk of 48-hour deterioration 3
This is perhaps the most clinically useful bedside parameter—patients with MAP >80 mmHg have an exceptionally low deterioration risk.
Cardiac Index and Normotensive Shock
- 34% of intermediate-risk patients have isolated hypoperfusion without hypotension (normotensive shock) 1
- These patients represent a higher-risk subset within the intermediate category
Echocardiographic Parameters
- Low stroke volume (MOD <36 mL vs. 50 mL in stable patients) strongly predicts deterioration with OR 0.72 2
- TAPSE <1.54 cm versus 1.81 cm in stable patients 2
- Worsening TAPSE on repeat echo increases 30-day mortality risk 5.26-fold 5
Clinical Markers
- Syncope at presentation: 2.8-fold increased risk 6
- Heart rate normalization within 48 hours: Only 1.4% subsequent deterioration risk 4
- SaO2 <90%: 5.3-fold increased risk 7
Practical Risk Stratification Algorithm
For a patient with intermediate-risk PE, assess:
MAP at admission
- If >80 mmHg → ~2-3% deterioration risk (very low)
- If ≤81.5 mmHg → proceed to step 2
Clinical presentation
Echocardiographic findings
Biomarker trajectory
- Persistently elevated NT-proBNP/troponin at 24-48 hours → higher risk 8
- Normalization suggests lower subsequent risk
Common Pitfalls
- Don't rely on single time-point assessment: Serial evaluation within the first 48-72 hours is critical, as deterioration patterns emerge over time 1, 5
- Don't assume all "intermediate-risk" patients are equivalent: The range spans from 2% to 24% deterioration risk depending on specific parameters 1, 4
- Don't overlook normotensive shock: One-third of intermediate-risk patients have hypoperfusion despite normal blood pressure 1
Bottom Line
While the textbook answer is approximately 10 out of 100, the actual risk for any individual patient ranges from as low as 2% (MAP >80 mmHg, normalizing vital signs) to as high as 24% (multiple adverse features present) 1, 3, 4. MAP >80 mmHg is the single most powerful reassuring finding, with a negative predictive value of 97.7% 1, 3.